Bo Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bo Zhang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Hua Zhong
Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine. No. 241, West Huaihai Road, Shanghai 200030, China
3 shared publications - Feng Pan
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Jiajun Teng
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Jialin Qian
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Jun Lu
Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Meili Ma
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 11 June 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Efficacy and safety of first-line oral vinorelbine plus firmonertinib in refractory EGFR -mutated non-small cell lung cancer: study protocol of a multicenter, non-randomized, two-cohort study
Background: Although combinations of third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with chemotherapy or amivantamab have significantly improved progression-free survival (PFS) and overall survival (OS) compared with EGFR-TKI monotherapy in EGFR -mutated advanced non-small cell lung cancer (NSCLC), the increased toxicities and requirement for intravenous administration of chemotherapy limit their practicality. Patients with EGFR -mutated advanced NSCLC who develop M1c2 disease or exhibit elevated programmed death-ligand 1 (PD-L1) expression represent a clinically refractory subgroup with a high unmet need for effective and convenient combination strategies. Objectives: This study is designed to evaluate the efficacy and safety of an all-oral regimen combining vinorelbine and firmonertinib (a third-generation EGFR-TKI) as first-line treatment in this refractory population. Design: This open-label, non-randomized, two-cohort study is conducted at two centers in China. Systematic treatment-naïve patients with histopathology confirmed EGFR -mutated (exon 19 deletion or exon 21 L858R mutation) NSCLC, who are not amenable to curative surgery or radiotherapy, will be recruited. Cohort 1 will comprise 54 metastatic NSCLC patients with M1c2 disease, and Cohort 2 will consist of 77 locally advanced or metastatic NSCLC patients with a PD-L1 tumor proportion score of ⩾25%. Recruitment began on December 11, 2025, and is currently in progress. Methods and analysis: During the one-cycle safety run-in period, six patients received oral vinorelbine (60 mg/m 2 on days 1 and 8) plus firmonertinib (80 mg once daily) as the starting dose. Dosing regimen for the subsequent expansion cohort will be determined based on the safety data from the safety run-in period. The treatment cycle is repeated every 3 weeks and will continue until disease progression or unacceptable toxicity. The primary endpoint is investigator-assessed PFS. Secondary endpoints are objective response rate, disease control rate, OS, and safety. Ethics: This study has received ethics approval from the ethical committee of the Shanghai Chest Hospital (approval number: IS25204). Discussion: To the best of our knowledge, this study represents the first evaluation of vinorelbine plus firmonertinib in EGFR -mutated locally advanced or metastatic NSCLC with M1c2 disease or elevated PD-L1 expression, aiming to provide an effective, tolerable, and convenient all-oral treatment option for this refractory population. Trial registration: The study protocol (version 1.2; July 18, 2025) was registered on October 24, 2025, at the Chinese Clinical Trial Registry (ChiCTR2500111096).
- 11 June 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Open AccessEfficacy and safety of first-line oral vinorelbine plus firmonertinib in refractory EGFR -mutated non-small cell lung cancer: study protocol of a multicenter, non-randomized, two-cohort study
Background: Although combinations of third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with chemotherapy or amivantamab have significantly improved progression-free survival (PFS) and overall survival (OS) compared with EGFR-TKI monotherapy in EGFR -mutated advanced non-small cell lung cancer (NSCLC), the increased toxicities and requirement for intravenous administration of chemotherapy limit their practicality. Patients with EGFR -mutated advanced NSCLC who develop M1c2 disease or exhibit elevated programmed death-ligand 1 (PD-L1) expression represent a clinically refractory subgroup with a high unmet need for effective and convenient combination strategies. Objectives: This study is designed to evaluate the efficacy and safety of an all-oral regimen combining vinorelbine and firmonertinib (a third-generation EGFR-TKI) as first-line treatment in this refractory population. Design: This open-label, non-randomized, two-cohort study is conducted at two centers in China. Systematic treatment-naïve patients with histopathology confirmed EGFR -mutated (exon 19 deletion or exon 21 L858R mutation) NSCLC, who are not amenable to curative surgery or radiotherapy, will be recruited. Cohort 1 will comprise 54 metastatic NSCLC patients with M1c2 disease, and Cohort 2 will consist of 77 locally advanced or metastatic NSCLC patients with a PD-L1 tumor proportion score of ⩾25%. Recruitment began on December 11, 2025, and is currently in progress. Methods and analysis: During the one-cycle safety run-in period, six patients received oral vinorelbine (60 mg/m 2 on days 1 and 8) plus firmonertinib (80 mg once daily) as the starting dose. Dosing regimen for the subsequent expansion cohort will be determined based on the safety data from the safety run-in period. The treatment cycle is repeated every 3 weeks and will continue until disease progression or unacceptable toxicity. The primary endpoint is investigator-assessed PFS. Secondary endpoints are objective response rate, disease control rate, OS, and safety. Ethics: This study has received ethics approval from the ethical committee of the Shanghai Chest Hospital (approval number: IS25204). Discussion: To the best of our knowledge, this study represents the first evaluation of vinorelbine plus firmonertinib in EGFR -mutated locally advanced or metastatic NSCLC with M1c2 disease or elevated PD-L1 expression, aiming to provide an effective, tolerable, and convenient all-oral treatment option for this refractory population. Trial registration: The study protocol (version 1.2; July 18, 2025) was registered on October 24, 2025, at the Chinese Clinical Trial Registry (ChiCTR2500111096).
- Open Access
- 8 November 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e64950
Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study
Background: Immunotherapy has significantly advanced lung cancer treatment, particularly in nonsquamous non–small cell lung cancer (NSCLC), with overall response rates between 50% and 60%. However, about 30% of patients only achieve a stable disease state. Cryoablation has shown potential to enhance immunotherapy by modifying the tumor’s immune microenvironment through the release of antigens and immune factors. Addressing how to boost the immune response in these patients is critical. Objective: This study aims to investigate the efficacy and safety of immunochemotherapy in combination with cryoablation as a first-line treatment for advanced NSCLC. Methods: This is a phase II, pilot, open-label, single arm, single center, interventional study. Patients with stage IIIB to IIIC or IV NSCLC with T staging ranging from T1 to T2b will receive sintilimab (200 mg/m2 every 3 weeks) and chemotherapy. After 2 cycles, the feasibility of cryoablation will be considered for those with stable disease by a multidisciplinary team. Cryoablation with 3 freeze-thaw cycles will be performed for the main lesion. The third cycle of systemic therapy will begin 7 (SD 3) days after cryoablation. A total of 20 patients will be enrolled. Treatment will continue until the disease progresses, there is unacceptable toxicity, a participant withdraws consent, other discontinuation criteria are met, or the study reaches completion. The primary objective is to assess progression-free survival (PFS). The secondary objective is to assess efficacy through duration of response, disease control rate, overall survival (OS), and the safety profile. The exploratory objective is to investigate and compare immune factor changes after 2 cycles of immunochemotherapy and at 1, 3, and 7 days after cryoablation. Survival time will be estimated using the Kaplan-Meier method to calculate median PFS and OS. Any adverse events that occur during the trial will be promptly recorded. Results: The project was funded in 2024, and enrollment will be completed in 2025. The first results are expected to be submitted for publication in 2027. Conclusions: This study will provide evidence for the efficacy and safety of the combination of immunochemotherapy and cryoablation as a first-line treatment for advanced NSCLC. Although it has a limited sample size, the findings of this study will be used in the future to inform the design of a fully powered, 2-arm, larger-scale study. Trial Registration: ClinicalTrials.gov NCT06483009; https://clinicaltrials.gov/study/NCT06483009 International Registered Report Identifier (IRRID): PRR1-10.2196/64950
- 8 November 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e64950
Open AccessEfficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study
Background: Immunotherapy has significantly advanced lung cancer treatment, particularly in nonsquamous non–small cell lung cancer (NSCLC), with overall response rates between 50% and 60%. However, about 30% of patients only achieve a stable disease state. Cryoablation has shown potential to enhance immunotherapy by modifying the tumor’s immune microenvironment through the release of antigens and immune factors. Addressing how to boost the immune response in these patients is critical. Objective: This study aims to investigate the efficacy and safety of immunochemotherapy in combination with cryoablation as a first-line treatment for advanced NSCLC. Methods: This is a phase II, pilot, open-label, single arm, single center, interventional study. Patients with stage IIIB to IIIC or IV NSCLC with T staging ranging from T1 to T2b will receive sintilimab (200 mg/m2 every 3 weeks) and chemotherapy. After 2 cycles, the feasibility of cryoablation will be considered for those with stable disease by a multidisciplinary team. Cryoablation with 3 freeze-thaw cycles will be performed for the main lesion. The third cycle of systemic therapy will begin 7 (SD 3) days after cryoablation. A total of 20 patients will be enrolled. Treatment will continue until the disease progresses, there is unacceptable toxicity, a participant withdraws consent, other discontinuation criteria are met, or the study reaches completion. The primary objective is to assess progression-free survival (PFS). The secondary objective is to assess efficacy through duration of response, disease control rate, overall survival (OS), and the safety profile. The exploratory objective is to investigate and compare immune factor changes after 2 cycles of immunochemotherapy and at 1, 3, and 7 days after cryoablation. Survival time will be estimated using the Kaplan-Meier method to calculate median PFS and OS. Any adverse events that occur during the trial will be promptly recorded. Results: The project was funded in 2024, and enrollment will be completed in 2025. The first results are expected to be submitted for publication in 2027. Conclusions: This study will provide evidence for the efficacy and safety of the combination of immunochemotherapy and cryoablation as a first-line treatment for advanced NSCLC. Although it has a limited sample size, the findings of this study will be used in the future to inform the design of a fully powered, 2-arm, larger-scale study. Trial Registration: ClinicalTrials.gov NCT06483009; https://clinicaltrials.gov/study/NCT06483009 International Registered Report Identifier (IRRID): PRR1-10.2196/64950
- Open Access
- 31 July 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study (Preprint)
BACKGROUND Immunotherapy has significantly advanced lung cancer treatment, particularly in nonsquamous non–small cell lung cancer (NSCLC), with overall response rates between 50% and 60%. However, about 30% of patients only achieve a stable disease state. Cryoablation has shown potential to enhance immunotherapy by modifying the tumor’s immune microenvironment through the release of antigens and immune factors. Addressing how to boost the immune response in these patients is critical. OBJECTIVE This study aims to investigate the efficacy and safety of immunochemotherapy in combination with cryoablation as a first-line treatment for advanced NSCLC. METHODS This is a phase II, pilot, open-label, single arm, single center, interventional study. Patients with stage IIIB to IIIC or IV NSCLC with T staging ranging from T1 to T2b will receive sintilimab (200 mg/m2 every 3 weeks) and chemotherapy. After 2 cycles, the feasibility of cryoablation will be considered for those with stable disease by a multidisciplinary team. Cryoablation with 3 freeze-thaw cycles will be performed for the main lesion. The third cycle of systemic therapy will begin 7 (SD 3) days after cryoablation. A total of 20 patients will be enrolled. Treatment will continue until the disease progresses, there is unacceptable toxicity, a participant withdraws consent, other discontinuation criteria are met, or the study reaches completion. The primary objective is to assess progression-free survival (PFS). The secondary objective is to assess efficacy through duration of response, disease control rate, overall survival (OS), and the safety profile. The exploratory objective is to investigate and compare immune factor changes after 2 cycles of immunochemotherapy and at 1, 3, and 7 days after cryoablation. Survival time will be estimated using the Kaplan-Meier method to calculate median PFS and OS. Any adverse events that occur during the trial will be promptly recorded. RESULTS The project was funded in 2024, and enrollment will be completed in 2025. The first results are expected to be submitted for publication in 2027. CONCLUSIONS This study will provide evidence for the efficacy and safety of the combination of immunochemotherapy and cryoablation as a first-line treatment for advanced NSCLC. Although it has a limited sample size, the findings of this study will be used in the future to inform the design of a fully powered, 2-arm, larger-scale study. CLINICALTRIAL ClinicalTrials.gov NCT06483009; https://clinicaltrials.gov/study/NCT06483009 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/64950
- 31 July 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEfficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study (Preprint)
BACKGROUND Immunotherapy has significantly advanced lung cancer treatment, particularly in nonsquamous non–small cell lung cancer (NSCLC), with overall response rates between 50% and 60%. However, about 30% of patients only achieve a stable disease state. Cryoablation has shown potential to enhance immunotherapy by modifying the tumor’s immune microenvironment through the release of antigens and immune factors. Addressing how to boost the immune response in these patients is critical. OBJECTIVE This study aims to investigate the efficacy and safety of immunochemotherapy in combination with cryoablation as a first-line treatment for advanced NSCLC. METHODS This is a phase II, pilot, open-label, single arm, single center, interventional study. Patients with stage IIIB to IIIC or IV NSCLC with T staging ranging from T1 to T2b will receive sintilimab (200 mg/m2 every 3 weeks) and chemotherapy. After 2 cycles, the feasibility of cryoablation will be considered for those with stable disease by a multidisciplinary team. Cryoablation with 3 freeze-thaw cycles will be performed for the main lesion. The third cycle of systemic therapy will begin 7 (SD 3) days after cryoablation. A total of 20 patients will be enrolled. Treatment will continue until the disease progresses, there is unacceptable toxicity, a participant withdraws consent, other discontinuation criteria are met, or the study reaches completion. The primary objective is to assess progression-free survival (PFS). The secondary objective is to assess efficacy through duration of response, disease control rate, overall survival (OS), and the safety profile. The exploratory objective is to investigate and compare immune factor changes after 2 cycles of immunochemotherapy and at 1, 3, and 7 days after cryoablation. Survival time will be estimated using the Kaplan-Meier method to calculate median PFS and OS. Any adverse events that occur during the trial will be promptly recorded. RESULTS The project was funded in 2024, and enrollment will be completed in 2025. The first results are expected to be submitted for publication in 2027. CONCLUSIONS This study will provide evidence for the efficacy and safety of the combination of immunochemotherapy and cryoablation as a first-line treatment for advanced NSCLC. Although it has a limited sample size, the findings of this study will be used in the future to inform the design of a fully powered, 2-arm, larger-scale study. CLINICALTRIAL ClinicalTrials.gov NCT06483009; https://clinicaltrials.gov/study/NCT06483009 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/64950
- Open Access
- 1 December 2018
- Published by KEAI Publishing in Digital Chinese Medicine
- Vol. 1 (4) , 310-315
Effects of Pachyman in Combination with Vinorelbine and Cisplatin on Tumor Growth and the Expression of EGFR and K-ras in Mice with Lung Cancer
- 1 December 2018
- Published by KEAI Publishing in Digital Chinese Medicine
- Vol. 1 (4) , 310-315
Open AccessEffects of Pachyman in Combination with Vinorelbine and Cisplatin on Tumor Growth and the Expression of EGFR and K-ras in Mice with Lung Cancer